MAPT and Alzheimer disease: One such model, the TgF344-AD rat, is characterized by the presence of human APPswe and PS1ΔE9 mutations, leading to the progressive build-up of amyloid beta (Aβ) deposits starting at 6 months of age (Cohen et al., 2013; Joo et al., 2017), accompanied by accumulation of phosphorylated tau (pTau) (Joo et al., 2017; Rorabaugh et al., 2017), gliosis, neuronal loss and cognitive impairments similar to those observed in human AD (Braak et al., 2011; Cohen et al., 2013; Munoz-Moreno et al., 2018).